News Sentiment

PVLA sentiment intelligence

Palvella Therapeutics, Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 157.24 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+8.6% over one week, +39.0% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

Palvella Therapeutics (PVLA) Sees Significant Decline

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction 8.6% Price confirming higher
Trend fit Trend active 39.0% over four weeks
Fair value 131.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 39
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
TradingView 11
Investing.com 4
Quiver Quantitative 4
simplywall.st 4
Stock Titan 3
Moomoo 3
GlobeNewswire 3

Event Lens

What the news is about

Classified themes
Market update 39
Earnings 16
Analyst action 4
Deals and strategy 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 62
Investing.com South Africa Direct company coverage

Palvella Therapeutics COO Kathleen Goin sells $476,372 in stock By Investing.com

Kathleen Goin, COO of Palvella Therapeutics (NASDAQ:PVLA), sold 4,302 shares worth $476,372 on June 17, 2026. This sale followed the acquisition of shares through stock option exercises valued at $34,883 and was executed under a Rule 10b5-1 trading plan. Despite the sale, the sto

Tone
Neutral 50/100
Event
Deals and strategy
Published
23 Jun 2026 02:40
Source
Investing.com South Africa
Investing.com Direct company coverage

Palvella Therapeutics COO Kathleen Goin sells $476,372 in stock

Kathleen Goin, COO of Palvella Therapeutics (NASDAQ:PVLA), sold 4,302 shares of PVLA stock valued at $476,372 on June 17, 2026, after exercising stock options worth $34,883. The transactions were conducted under a Rule 10b5-1 trading plan. Following the sales, Ms. Goin holds no d

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 21:10
Source
Investing.com
grafa.com Direct company coverage

Palvella Therapeutics granted FDA rolling review for QTORIN

The FDA has granted Palvella Therapeutics a rolling review for its rare genetic disease drug candidate, QTORIN rapamycin. This treatment targets microcystic lymphatic malformations, a condition affecting approximately 30,000 individuals in the US with no other approved therapies.

Tone
Positive 86/100
Event
Market update
Published
22 Jun 2026 16:10
Source
grafa.com
MSN Direct company coverage

Palvella shares advance after FDA grants rolling review for rare disease therapy

Palvella shares are advancing after the FDA granted a rolling review for its rare disease therapy. A rolling review allows a drug company to submit sections of its New Drug Application (NDA) to the FDA as they are completed, rather than waiting for all sections to be finalized. T

Tone
Positive 72/100
Event
Market update
Published
22 Jun 2026 14:12
Source
MSN